Alembic Pharmaceuticals receives USFDA tentative approval for heart failure drug
Ivabradine Tablets, 5 mg and 7.5 mg have an estimated market size of US $ 102 million for twelve months ending December 2021 according to IQVIA
Ivabradine Tablets, 5 mg and 7.5 mg have an estimated market size of US $ 102 million for twelve months ending December 2021 according to IQVIA
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older
The Board of Directors of Alembic Pharmaceuticals have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021.
The US business faced price erosion due to increased competition.
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5%/0.3%, of Bausch & Lomb
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
Sumatriptan injection is indicated in adults for the acute treatment of migraine
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Subscribe To Our Newsletter & Stay Updated